ALSEN Share Price Performance
Recent ALSEN News & Updates
No updates
Sensorion SA Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.086
- Gross Margin
- 100.00%
- Net Profit Margin
- -390.38%
- Debt/Equity Ratio
- 1.7%
Sensorion SA Competitors
About ALSEN
- Founded
- 2009
- Employees
- 63
- CEO
- WebsiteView website
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing impairment. It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1/2 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene. The company was incorporated in 2009 and is headquartered in Montpellier, France.
French Market Performance
- 7 Days: -0.006%
- 3 Months: 2.5%
- 1 Year: 3.1%
- Year to Date: 4.6%
Over the last 7 days, the market has risen 1.3%, driven by gains in the Healthcare and Consumer Discretionary sectors of 6.1% and 2.4%, respectively. In contrast, the Information Technology sector is lagging, dropping 7.1%. In the last year, the market has climbed 3.8%. Looking forward, earnings are forecast to grow by 13% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading